Adjunctive brexpiprazole for the treatment of major depressive disorder

References

• Bloom BS. Prevalence and economic effects of depression. Manag Care. 2004 Jun;13(6 Suppl Depression):9–16.
   PubMedGoogle Scholar
• Otsuka. REXULTI (Brexpiprazole) tablets, for oral use. Prescribing Information. Revised 2015 July. [cited 2016 June 26]. Available from: http://wwww.otsuka-us.com/Products/Documents/Rexulti.PI.pdf
   Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015b Sep;76:1232–1240.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015a Sep;76:1224–1231.
   PubMed Web of Science ®Google Scholar
• Kantor ED, Rehm CD, Js H, et al. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015 Nov 3;314:1818–1831.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009 Jan;19:34–40.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009 Aug;23:627–647.
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, et al. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007 Dec;9:449–459.
   PubMedGoogle Scholar
• American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(Suppl 4):1–45.
   Web of Science ®Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British association for psychopharmacology guidelines. J Psychopharmacol. 2015 May;29:459–525.
   PubMed Web of Science ®Google Scholar
• Han C, Wang SM, Kato M, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13:851–870.
   PubMed Web of Science ®Google Scholar
• Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 6):16–25.
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010 Dec 8;12:CD008121.
   PubMed Web of Science ®Google Scholar
• Sagud M, Mihaljević-Peleš A, Begić D, et al. Antipsychotics as antidepressants: what is the mechanism?. Psychiatr Danub. 2011;23:302–307.
   PubMed Web of Science ®Google Scholar
• Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry. 2013;74(Suppl 2):19–24.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350:589–604.
   PubMed Web of Science ®Google Scholar
• Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry. 2003;53:193–203.
   PubMed Web of Science ®Google Scholar
• De Vry J, Schreiber R, Melon C, et al. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol. 2004;14:487–495.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Iyo M, Hashimoto K. Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia. Curr Psychiatry Rev. 2012;8:140–150.
   Google Scholar
• Yoshimi N, Fujita Y, Ohgi Y, et al. Effect of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 2014;124:245–249.
   PubMed Web of Science ®Google Scholar
• Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25:356–364.
   PubMed Web of Science ®Google Scholar
• Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 1994;55:479–483.
   PubMed Web of Science ®Google Scholar
• Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996 May;5:389–402.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009 Sep;166:980–991.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Davis RE. Role of 5-HT2A receptor antagonists in the treatment of insomnia. Nat Sci Sleep. 2010;2:139–150.
   PubMedGoogle Scholar
• Salamone JD, Correa M, Yohn S, et al. The pharmacology of effort-related choice behavior: dopamine, depression, and individual differences. Behav Processes. 2016;127:3–17.
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–389.
   PubMed Web of Science ®Google Scholar
• Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014 Dec;351:585–595.
   PubMed Web of Science ®Google Scholar
• Das S, Barnwal P, Winston AB, et al. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6:39–54.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptors. J Clin Psychiatry. 2001 Nov;62:841–842.
   PubMed Web of Science ®Google Scholar
• Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996;57(Suppl 11):40–52.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother. 2005 Oct;6:2091–2101.
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs. 2007 Jul;8:539–554.
   PubMed Web of Science ®Google Scholar
• Casey DE, Sands EE, Heisterberg J, et al. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl). 2008 Oct;200:317–331.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Nisima K, Katoh S, et al. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem Int. 2002;40:355–360.
   PubMed Web of Science ®Google Scholar
• Gobert A, Rivet JM, Cistarelli JM, et al. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem. 1997;68:1326–1329.
   PubMed Web of Science ®Google Scholar
• Dremencov E, Newman ME, Kinor N, et al. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology. 2005;48:34–42.
   PubMed Web of Science ®Google Scholar
• Silver H, Chertkow Y, Weinreb O, et al. Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?. Neurotherapeutics. 2009;6:86–93.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016 Apr;21:123–127.
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–526.
   PubMed Web of Science ®Google Scholar
• Howland RH. Brexpiprazole: another multipurpose antipsychotic drug?. J Psychosoc Nurs Ment Health Serv. 2015 Apr;53:23–25.
   Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382–389.
   PubMed Web of Science ®Google Scholar
• Sheehan DV. The anxiety disease. New York (NY): Charles Scribner & Sons; 1983.
   Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338. Rockville (MD): National Institute of Mental Health; 1976. p. 218–222.
   Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55.
   PubMed Web of Science ®Google Scholar
• Krystal A, Mittoux A, Meisels P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbances: an exploratory study. Poster presented at: The U.S. Psychiatric & Mental Health congress (UPMHC); 2015 Sep 10-13; San Diego, California.
   Google Scholar
• Fava M, Ménard F, Davidsen CK, et al. Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry. 2016 July 5. doi:10.4088/JCP.15m10470. [Epub ahead of print]
   Google Scholar
• Weisler RH, Ota A, Tsuneyoshi K, et al. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord. 2016 Jun 4;204:40–47.
   PubMed Web of Science ®Google Scholar
• Davis L, Ota A, Perry P, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study. Poster presented at: the 168th American Psychiatric Association Annual Meeting; 2015 May 16-20; Toronto, Canada.
   Google Scholar
• McIntyre RS, Weiller E, Zhang P, et al. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016 Sep 1;201:116–123.
   PubMed Web of Science ®Google Scholar
• Weiss C, Skuban A, Hobart M, et al. Incidence, onset, duration and severity of akathisia with adjunctive brexpiprazole (OPC-34712) in major depressive disorder: analysis of two pivotal studies. Poster presented at: the 55th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP); 2015 June 22-25; Miami, Florida
   Google Scholar
• Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7:303–312.
   PubMed Web of Science ®Google Scholar